TrialCancer immunology, immunotherapy : CII2007

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients.

François Ghiringhelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.